Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.

Adults should discuss with their doctors about whether this vaccine is necessary. It is recommended that adults 50 and older ...

GlaxoSmithKline’s shingles vaccine Shingrix has gained the unanimous backing of an FDA advisory committee. The Vaccines and Related Biological Products Advisory Committee vote sets the product ...

The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.

30, missing market expectations of 238 million pounds, while sales of shingles vaccine, Shingrix, fell 7% to 739 million pounds, also below estimates in a company compiled consensus. Walmsley told ...

Amezosvatein and Shingrix are adjuvanted recombinant protein subunit vaccines targeting glycoprotein E (gE), the most abundant glycoprotein expressed on the surface of the varicella zoster virus ...

Zero shingles cases after 18.8 months follow-up in 619 patients receiving any dose of amezosvatein, a development-stage adjuvanted subunit ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

Two of GSK Plc’s blockbuster vaccines delivered lower than expected sales in the third quarter after the British drugmaker ...

In its first set of financial figures since spinning off its consumer health division, GSK has reported a 19% increase in revenues, driven by burgeoning demand for its shingles vaccine Shingrix ...

-- Positive data from 876-patient head-to-head trial versus Shingrix ® shows amezosvatein elicits robust humoral and cellular immune responses with comparatively lower reactogenicity ...